John Nosenzo, Chief Commercial Officer at Bioventus Inc. (BVS), sold 534 shares at $11.99 ($6K) on 2022-02-14, disclosed to the SEC on 2022-02-15.
Scheduled sale ($6k) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| BVS | BUY | 2021-04-05 | $7K | — | Filing → |